{"id":24842,"date":"2024-07-16T11:05:25","date_gmt":"2024-07-16T09:05:25","guid":{"rendered":"https:\/\/www.izb-online.de\/?p=24842"},"modified":"2024-07-16T11:08:48","modified_gmt":"2024-07-16T09:08:48","slug":"catalym-announces-new-financing-of-150m-to-support-broad-phase-2b-development-program-for-visugromab","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/catalym-announces-new-financing-of-150m-to-support-broad-phase-2b-development-program-for-visugromab\/","title":{"rendered":"CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text css=”” el_class=”gco-magazine–title”]<\/p>\n

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab<\/h1>\n

[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-lead”]CatalYm, an IZB-based \u00a0immuno-oncology company focused on GDF-15 neutralising therapies, has closed a Series D financing.[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine–post-date”]July, 2024[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”24839″ img_size=”full” css=””][vc_column_text css=”” el_class=”gco-magazine-copyright”]\u00a9 CatalYm[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-picture-discription”]Data show that treatment with visugromab combined with the anti-PD-1 antibody, nivolumab achieves deep and durable anti-tumoral activity.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text css=””]<\/p>\n

\u201cWe were initially drawn to the exciting biology around GDF-15 and found CatalYm to be at the forefront of the field. We believe this approach has the potential to significantly increase durability and deepen responses, unlocking the full potential of I\/O treatments. We are excited to support this fantastic team, and syndicate, in running robust clinical studies in a variety of promising indications.\u201d<\/h6>\n

Jon Edwards, Managing Partner at Bioqube Ventures<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text css=””]The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion\u2019s Growth Opportunities Fund (\u201cForbion Growth\u201d), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius also participated in the round. The proceeds will fund the expansion of the company\u2019s broad Phase 2b development of visugromab into randomized Phase 2b studies in select checkpoint na\u00efve frontline and second-line treatment settings. Visugromab has already demonstrated outstanding antitumor activity in combination with checkpoint inhibitor treatment.<\/p>\n

Visugromab is a humanized monoclonal antibody engineered to neutralize the tumorproduced Growth Differentiation Factor-15 (GDF-15), which acts as a key regulator of immune resistance to cancer therapies. CatalYm recently reported<\/a> impressive follow-up results from its ongoing \u201cGDFATHER\u201d Phase 1\/2a trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 1\/2a) (NCT04725474)<\/a> in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago. The data showed that treatment with visugromab combined with the anti-PD-1 antibody, nivolumab achieves deep and durable anti-tumoral activity, including several complete responses in anti-PD-1\/PD-L1 relapsed\/refractory patients with non-small cell lung cancer (NSCLC), urothelial cancer (UC) or hepatocellular carcinoma (HCC).<\/p>\n

\u201cThis substantial raise and strong syndicate recognize our achievements as a company and emphasize the excellent results of visugromab and our broad Phase 2b clinical program. We continue to demonstrate visugromab\u2019s potential to induce cancer remission depth and durability across multiple solid tumor indications emphasizing the substantial role visugromab could play in a novel anti-cancer therapy regimen,\u201d said Phil L\u2019Huillier, Managing Director and Chief Executing Officer at CatalYm. <\/strong>\u201cWe are building significant momentum for CatalYm\u2019s development strategy and look forward to the support of these high-profile new and existing international investors, who share our vision of breaking immunosuppressive barriers to improve therapeutic outcomes\u201d.<\/p>\n

In conjunction with the close of the financing, Colleen Cuffaro, Partner at Canaan, Jon Edwards, Managing Partner at Bioqube Ventures and Otello Stampacchia, Managing Director and Founder at Omega Funds, will join the CatalYm Board of Directors<\/a>. Stefan Luzi, Partner at Gilde Healthcare will join as Board Observer.<\/p>\n

\u201cThe recent data presented at ASCO highlight visugromab\u2019s highly differentiated therapeutic profile and validate the ability of Phil and his team to expeditiously execute on the company\u2019s clinical plan,\u201d commented Colleen Cuffaro, Partner at Canaan Partners.<\/strong> \u201cAs the company advances into expanded Phase 2b development, we are excited to provide our strategic guidance on the company\u2019s trajectory toward changing the current treatment regimens for hard-to-treat solid tumor indications.\u201d<\/p>\n

Jon Edwards, Managing Partner at Bioqube Ventures added:<\/strong> \u201cWe were initially drawn to the exciting biology around GDF-15 and found CatalYm to be at the forefront of the field. We believe this approach has the potential to significantly increase durability and deepen responses, unlocking the full potential of I\/O treatments. We are excited to support this fantastic team, and syndicate, in running robust clinical studies in a variety of promising indications.\u201d<\/p>\n

Founded in 2016 with support from Forbion Ventures Fund III and BGV, CatalYm is a leader in the development of a new class of cancer treatments aiming to prevent or reverse cancer resistance to checkpoint inhibition, chemotherapy and other targeted treatments. The approach neutralizes GDF-15, a critical immunosuppressant used by tumor cells to survive. With its broad Phase 2b development plan, the company targets high-need solid tumor indications including NSCLC, UC, HCC and bladder cancer where existing and acquired resistance are a major problem. CatalYm is now in preparations to launch further randomized, controlled studies in several major cancer indications in combination with checkpoint inhibitors and standard-of-care in first- and second-line treatment in the first half of 2025.<\/p>\n

About CatalYm
\n<\/strong>CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as safe and efficacious immune therapy for solid tumors. GDF-15, an immunosuppressant important for feto-maternal tolerance, is hijacked by cancer cells to evade immune system attack. Visugromab, CatalYm\u2019s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment. CatalYm is now advancing to Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy in a broad range of anti-cancer regimens.<\/p>\n

About Visugromab (CTL-002)
\n<\/strong>Visugromab is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation and tumor infiltration. Visugromab has demonstrated a good safety profile and potent and durable anti-tumor efficacy in combination with anti-PD-1 treatment in advanced cancer patients The antibody is currently being investigated in ongoing Phase 2a studies in multiple solid tumor indications.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n